Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.

Proceedings of the National Academy of Sciences of the United States of America - 3 May 2011

Katayama Ryohei, Khan Tahsin M, Benes Cyril, Lifshits Eugene, Ebi Hiromichi, Rivera Victor M, Shakespeare William C, Iafrate A John, Engelman Jeffrey A, Shaw Alice T

Abstract excerpt

The echinoderm microtubule-associated protein-like 4 (EML4)-anaplastic lymphoma kinase (ALK) fusion oncogene represents a molecular target in a small subset of non-small cell lung cancers (NSCLCs). This fusion leads to constitutive ALK activation with potent transforming activity. In a pivotal phase 1 clinical trial, the ALK tyrosine kinase inhibitor (TKI) crizotinib (PF-02341066) demonstrated impressive...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Crizotinib
Share to Immunoblotting

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Nude

Share to Oncogene Proteins, Fusion

Share to Organophosphorus Compounds

Share to Pyrazoles

Share to Pyridines

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 21502504
DOI: 10.1073/pnas.1019559108
PMCID: PMC3088626

Genes

ALK
EML4

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Therapeutic strategies to overcome crizotinib resistance in non-small cell lung cancers harboring the fusion oncogene EML4-ALK.PMID 21502504Read ↗

Mechanisms of Acquired Resistance to ALK Inhibitors and the Rationale for Treating ALK-positive Lung CancerSemantic proximity Read ↗

Crizotinib‐Resistant Mutants of EML4‐ALK Identified Through an Accelerated Mutagenesis ScreenSemantic proximity Read ↗

A new ALK inhibitor overcomes resistance to first- and second-generation inhibitors in NSCLC.Semantic proximity Read ↗

Dual ALK and EGFR inhibition targets a mechanism of acquired resistance to the tyrosine kinase inhibitor crizotinib in ALK rearranged lung cancer.Semantic proximity Read ↗

Amphiregulin triggered epidermal growth factor receptor activation confers in vivo crizotinib-resistance of EML4-ALK lung cancer and circumvention by epidermal growth factor receptor inhibitors.Semantic proximity Read ↗

ALK mutations conferring differential resistance to structurally diverse ALK inhibitors.Semantic proximity Read ↗

Targeted Inhibition of the Molecular Chaperone Hsp90 Overcomes ALK Inhibitor Resistance in Non–Small Cell Lung CancerSemantic proximity Read ↗

Activity of second-generation ALK inhibitors against crizotinib-resistant mutants in an NPM-ALK model compared to EML4-ALK.Semantic proximity Read ↗

Management of Resistance to First-Line Anaplastic Lymphoma Kinase Tyrosine Kinase Inhibitor Therapy.Semantic proximity Read ↗

Resistance to Crizotinib in Advanced Non-Small Cell Lung Cancer (NSCLC) with ALK Rearrangement: Mechanisms, Treatment Strategies and New Targeted Therapies.Semantic proximity Read ↗

Heterogeneous responses and resistant mechanisms to crizotinib in ALK-positive advanced non-small cell lung cancer.Semantic proximity Read ↗

A novel ALK secondary mutation and EGFR signaling cause resistance to ALK kinase inhibitors.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.